Clinical Science (journal)

Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH

Retrieved on: 
Friday, November 3, 2023

TARRYTOWN, N.Y., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new and updated data from its hematology pipeline will be shared in 19 abstracts at the American Society of Hematology (ASH) Annual Meeting from December 9 to 12 in San Diego, CA. These include research across six investigational medicines that span eight difficult-to-treat blood cancers and disorders. Together, these presentations showcase the diversity of approaches Regeneron is advancing through its hematology pipeline and its dedication to leading-edge research.

Key Points: 
  • These include research across six investigational medicines that span eight difficult-to-treat blood cancers and disorders.
  • Together, these presentations showcase the diversity of approaches Regeneron is advancing through its hematology pipeline and its dedication to leading-edge research.
  • Our data at ASH are a testament to our progress towards this ambition,” said L. Andres Sirulnik, M.D., Ph.D., Senior Vice President, Translational and Clinical Sciences, Hematology at Regeneron.
  • “In addition to new results from our pivotal trials evaluating odronextamab and linvoseltamab, we are presenting findings on our growing blood disorders pipeline.

Nanoscope Therapeutics Strengthens Research and Development Leadership with Appointment of Najam Sharif, PhD, DSc.

Retrieved on: 
Thursday, October 26, 2023

DALLAS, Oct. 26, 2023 /PRNewswire/ -- Nanoscope Therapeutics Inc. , a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced the appointment of Najam Sharif, PhD, DSc, a veteran in drug/device discovery and development, as Vice President of Global Research and Development.

Key Points: 
  • DALLAS, Oct. 26, 2023 /PRNewswire/ -- Nanoscope Therapeutics Inc. , a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced the appointment of Najam Sharif, PhD, DSc, a veteran in drug/device discovery and development, as Vice President of Global Research and Development.
  • "We are delighted to welcome Naj to the Nanoscope team," said Sulagna Bhattacharya, Co-Founder and Chief Executive Officer of Nanoscope.
  • "I am honored to join Nanoscope, a company that I see as transformative in the field of ophthalmology.
  • Dr. Naj Sharif brings over three decades of experience in pharmaceutical drug/device discovery and development to Nanoscope, including specialized expertise in ophthalmology and neuroscience.

iFR and FFR are equally safe to diagnose and treat heart disease according to largest-ever analysis of new real-world, long-term data

Retrieved on: 
Thursday, October 26, 2023

iFR is an innovative pressure-derived index only offered by Philips that is used to assess coronary blockages during interventional procedures.

Key Points: 
  • iFR is an innovative pressure-derived index only offered by Philips that is used to assess coronary blockages during interventional procedures.
  • The analysis, “Long-term Safety of Revascularization Deferral Based on Instantaneous Wave-Free Ratio or Fractional Reserve,” compares patient outcomes using iFR and FFR in the diagnosis and treatment of heart disease.
  • The cumulative MACE risks for each group differentiated by 1.6% (iFR: 21.5%, FFR: 19.9%, HR 1.09 (95% CI: 0.90-1.33 at 5 years).
  • iFR is considered the Gold Standard for hyperemia-free physiologic assessment for measuring pressure in diagnostic and interventional procedures [1,4].

Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)

Retrieved on: 
Saturday, October 21, 2023

TARRYTOWN, N.Y., Oct. 21, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentation of key secondary endpoints for an investigational regimen of PD-1 inhibitor Libtayo® (cemiplimab) as a neoadjuvant monotherapy in stage II to IV resectable cutaneous squamous cell carcinoma (CSCC). The results from an international Phase 2 trial were presented in an oral session at the European Society for Medical Oncology (ESMO) Congress 2023 and concurrently published in The Lancet Oncology.

Key Points: 
  • “Advanced, resectable cutaneous squamous cell carcinoma can lead to reduced patient function and quality of life following the cumulative effects of treatment, typically surgery and radiation.
  • “Results from both the single-institution pilot trial and the multi-center Phase 2 trial found neoadjuvant cemiplimab was highly active in patients with resectable cutaneous squamous cell carcinoma.
  • These robust responses were durable, translating into event-free survival for the vast majority of patients at one and two years.”
    The multicenter, single-arm Phase 2 trial included two parts.
  • In Part 1, patients (n=79) received Libtayo 350 mg every three weeks for up to four doses, followed by curative-intent surgery.

Mediar Therapeutics Announces Clinical Candidates for Lead Fibrosis Programs, Strategic Collaborations and Key Leadership Addition

Retrieved on: 
Wednesday, October 25, 2023

CAMBRIDGE, Mass., Oct. 25, 2023 /PRNewswire/ -- Mediar Therapeutics Inc., a biotechnology company advancing a portfolio of first-in-class therapies that halt fibrosis progression, today announced several milestones that support clinical advancement of its portfolio of novel antibodies: the nomination of two clinical candidates, key strategic collaborations with Pfizer Ignite and WuXi Biologics, and the appointment of Jeffrey D. Bornstein, M.D., as Chief Medical Officer.

Key Points: 
  • Mediar's first candidate, MTX-463, is a first-in-class monoclonal antibody designed to neutralize the WISP-1 signaling that is elevated in and contributes to fibrosis progression.
  • Its second candidate, MTX-474, is a first-in-class monoclonal antibody designed to neutralize the EphrinB2 signaling that causes fibrosis advancement and may play a role in defining the fibrotic niche.
  • Mediar plans to advance both MTX-463 and MTX-474 into Phase 1 clinical development in 2024.
  • In addition, he directed development programs, including those focused on fibrosis, at Biogen, Gilead Sciences, Elan Pharmaceuticals and other early-stage biotechnology companies.

BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Small Cell Neuroendocrine Prostate Cancer

Retrieved on: 
Tuesday, October 10, 2023

NEW HAVEN, Conn., Oct. 10, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced positive overall survival (OS) data from its Phase 2 trial of BXCL701, the Company's investigational oral innate immune activator, in combination with KEYTRUDA® (pembrolizumab) in patients with small cell neuroendocrine prostate cancer (SCNC). As of a data cutoff of September 6, 2023, evaluable patients with SCNC (n=28) showed a median OS of 13.6 months (95% CI 10.9–NR), and a 12-month survival rate of 56.5%.

Key Points: 
  • “OS is the most meaningful measure by which the effectiveness of an oncology treatment is evaluated.
  • In 2023, there will be an estimated 288,3002 new patients with prostate cancer in the United States, with approximately 11,532 patients progressing to SCNC.
  • ET to discuss the data results from the Phase 2 trial of BXCL701.
  • Financial and other important information is routinely posted on and accessible through the Investors sections of its website at www.bioxceltherapeutics.com .

IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board

Retrieved on: 
Friday, October 6, 2023

LAWRENCEVILLE, N.J., Oct. 06, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Patrick Ott, M.D., Ph.D. to the Company’s scientific advisory board.

Key Points: 
  • LAWRENCEVILLE, N.J., Oct. 06, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Patrick Ott, M.D., Ph.D. to the Company’s scientific advisory board.
  • Dr. Ott is the Clinical Director of the Melanoma Disease Center and the Director, Clinical Sciences, of the Center for Immuno-Oncology at the Dana-Farber Cancer Institute.
  • He joins current scientific advisory board members Dan H. Barouch, M.D., Ph.D., Luke D. Handke, Ph.D., Sachet A. Shukla, Ph.D. and John W. Shiver, Ph.D.
    “We are honored that Dr. Ott has agreed to our scientific advisory board and believe that he will offer invaluable guidance as we further develop our technologies and advance our pipeline,” said Dr. Corinne Le Goff, president and chief executive officer of IMUNON.
  • Dr. Ott has been Principal Investigator of a first-in-human clinical trial testing a personalized vaccine (NeoVax) in patients with melanoma.

IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ET

Retrieved on: 
Wednesday, September 13, 2023

LAWRENCEVILLE, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapy and next-generation vaccines, reminds investors of its virtual R&D Day event tomorrow, September 14th beginning at 4:00 p.m. Eastern time. There is no need to pre-register for the event. A live and archived webcast will be available in the Scientific Presentations section of IMUNON’s website or here. Following management’s presentations, a Q&A session will be available via the chat function of the webcast.

Key Points: 
  • LAWRENCEVILLE, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapy and next-generation vaccines, reminds investors of its virtual R&D Day event tomorrow, September 14th beginning at 4:00 p.m. Eastern time.
  • There is no need to pre-register for the event.
  • A live and archived webcast will be available in the Scientific Presentations section of IMUNON’s website or here .
  • Following management’s presentations, a Q&A session will be available via the chat function of the webcast.

IMUNON to Host Virtual R&D Day on September 14th Beginning at 4:00 p.m. ET

Retrieved on: 
Thursday, September 7, 2023

LAWRENCEVILLE, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that it will hold a virtual R&D Day event on September 14th beginning at 4:00 p.m. Eastern time. Details about speakers and instructions on how to participate are below.

Key Points: 
  • LAWRENCEVILLE, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that it will hold a virtual R&D Day event on September 14th beginning at 4:00 p.m. Eastern time.
  • She is also Nancy C. Paduano Professor and Chair, Weill Cornell Medicine.
  • The virtual program will be held online beginning at 4:00 p.m. Eastern Time and is expected to last approximately 90 minutes.
  • Following management’s presentations, a Q&A session will be available via the chat function of the webcast.

Dr. Lyudmila Sarder Receives Rave Reviews from Lakeland Regional Health and AdventHealth Cancer Institute for Research

Retrieved on: 
Thursday, August 24, 2023

Lakeland, FL, Aug. 24, 2023 (GLOBE NEWSWIRE) -- AdventHealth Cancer Institute proudly unveiled findings that mark a significant milestone in the cancer research field.

Key Points: 
  • Lakeland, FL, Aug. 24, 2023 (GLOBE NEWSWIRE) -- AdventHealth Cancer Institute proudly unveiled findings that mark a significant milestone in the cancer research field.
  • Meanwhile, Lakeland Regional Health takes great pride in their resident physician who played a pivotal role in the research.
  • Photo: Dr. Lyudmila Sarder, MD, Resident Physician at Lakeland Regional Health, with Dr. Luis Daniel Lugo, MD, Program Director, Internal Medicine, Lakeland Regional Health | Lakeland, Florida
    Dr. Lyudmila Sarder , a Resident Physician at Lakeland Regional Health in Florida, and Dr. Sarfraz Ahmad , who is the Director of Clinical Research at the Gynecologic Oncology Department at AdventHealth Cancer Institute, collaborated to shed light on the emerging role of biosimilars in the treatment of HER2-positive breast cancer .
  • Photo: Dr. Lyudmila Sarder, MD, Resident Physician at Lakeland Regional Health with Dr. Sarfraz Ahmad, PhD, Director of Clinical Research at the Gynecologic Oncology Department at AdventHealth Cancer Institute | Orlando, Florida
    Dr. Sarder and Dr. Ahmad's research highlights the potential of biosimilars to alleviate the financial burden faced by cancer patients.